Pneumococcal Pneumonia: Worth the Shot

Pneumococcal Pneumonia: Worth the Shot

Joint Statement by the World Coalition on Adult Vaccination

- Advertisement -Pneumococcal Pneumonia: Worth the Shot

In the  current climate of COVID-19,  it is more  important than  ever  to ensure the  protection of older adults,  and those with underlying  chronic  conditions against  vaccine  preventable diseases. Maximising uptake of existing vaccines for respiratory diseases, such as influenza and pneumococcal pneumonia, reduces the annual burden of disease – including increased mortality, morbidity and healthcare costs – particularly in at-risk populations.

While  there has  recently been necessary focus  on  the  importance  for  influenza   vaccination from  governments,  public and private  health  leaders around the  world,  pneumococcal pneumonia has unfortunately been   left  out  of  the  spotlight.   This is especially worrying, considering people infected with influenza who contract pneumonia experience even worse outcomes and increased hospitalisation rates.

The World Coalition on Adult Vaccination calls on professional, patient and advocacy organisations, together with all levels of government to increase their investment in educating and encouraging older adults and those with chronic diseases to be vaccinated against  influenza  and pneumococcal pneumonia.

Pneumonia is a “common lung infection that can have many symptoms including difficulty in breathing, coughing, fever, fatigue, nausea and vomiting, chest pain, changes in heartbeat, confusion or delirium, and diarrhea”.  In North America, approximately 90% of deaths from an infectious illness are linked to pneumonia among those aged 65 years and older.

Research has also shown pneumonia to result in significant decline in functional ability of older adults.  A study of older adults in 13 French aged care facilities demonstrated that pneumonia was associated with loss of physical functioning and independence, such as the ability to bathe oneself or move from a bed to a chair.

Fortunately, and surprisingly unbeknown to many, there are vaccines to help prevent pneumonia among at-risk groups that significantly reduce pneumonia-related hospitalisations and costs along with broader, negative socio-economic impacts.  Despite the severity of pneumonia and availability of a vaccine, the vaccine is not widely discussed or recommended to prevent ill health and functional decline of those most at-risk.  In fact, research by Schneeberg et al. (2014) found that only 52% of older adults surveyed remembered their health care provider ever offering the pneumonia vaccine.

In line with  the WHO  Immunization  Agenda  2030, which envisions “A world where everyone, everywhere, at every age, fully benefits from vaccines” and in the context of the Decade of Healthy Ageing, the  World  Coalition  on Adult Vaccination urges  a cross-sectoral approach to investment and communication regarding  the  importance of vaccination against  respiratory disease to reduce functional decline, hospitalisations, morbidity,  mortality  and healthcare costs,  especially in light of the COVID-19 pandemic.

**The facts and views expressed are solely that of the author/authors and do not necessarily reflect that of the editorial board.

Latest news

Related news

Join us in Telegram for more news and updates.
Join us in Telegram for more news and updates.